RLYBClinical Trials•businesswire•
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Sentiment:Neutral (50)
Summary
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor. Additionally, Rallybio announced that the initial indicat
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 12, 2025 by businesswire